Vertex cystic fibrosis drug cocktails appear to hit the mark in trials
Shares of Vertex Pharmaceuticals soared in after-hours trading Tuesday after the company announced that three separate combinations of its experimental cystic fibrosis drugs had performed well in early- and mid-stage trials. The news brings the Boston-based company one important step closer to developing a treatment for nearly all patients with the lung disease. It also boosted its stock by around 25 percent by 4:30 p.m. If the stock increase holds until tomorrow's open, it would add nearly $9 billion… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 18, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

' Just What We Dreamed.' New Vertex Drugs Show Dramatic Benefit Against Cystic Fibrosis
Three different three-drug regimens all provided dramatic results against cystic fibrosis, a fatal disease of the lungs and digestive system that afflicts 75,000 people. “This is just what we dreamed would someday happen,” says Francis Collins, the director of the National Institutes of Health (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 18, 2017 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:VRTX NASDAQ:GLPG Source Type: news

Two recent scientific advances underscore an encouraging future for precision medicine at FDA
By: Janet Woodcock, M.D. FDA helps bring precision medicine – in the form of targeted therapies — to people living with diseases that have specific genetic features. Two recent FDA drug approvals point to an encouraging future for “precision medicine” — an approach for disease treatment that tailors medical therapies, including medications, to the needs of individual patients. These approvals involve diseases resulting from particular genetic characteristics identified by laboratory testing. In mid-May, FDA announced that we expanded the approval of Kalydeco (ivacaftor), enabling a larger num...
Source: Mass Device - July 17, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Blog FDA Voice Source Type: news

Vertex inks another reimbursement deal in Europe for top-selling drug
Since winning FDA approval in 2015 for Orkambi, Vertex Pharmaceuticals has been slowly expanding access to the pricey cystic fibrosis drug across Europe by signing reimbursement deals with various countries. On Thursday, Boston-based Vertex (Nasdaq: VRTX) said it had inked another reimbursement deal for Orkambi, its best-selling drug, this time with officials in Italy. The agreement with the Italian Medicines Agency will make the drug available to “hundreds of eligible patients” in the country… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 13, 2017 Category: American Health Authors: Max Stendahl Source Type: news

Bakaletz Lab biofilm work published in Proceedings of the National Academy of Sciences
(Nationwide Children's Hospital) The laboratory of Lauren Bakaletz, PhD, director, Center for Microbial Pathogenesis and vice president of basic sciences, The Research Institute at Nationwide Children's, studied the biofilm construction capabilities of nontypeable Haemophilus influenzae (NTHI), a bacterium responsible for sinusitis, pneumonia, exacerbations of cystic fibrosis and COPD, bronchitis and ear infections. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 13, 2017 Category: International Medicine & Public Health Source Type: news

Synspira ’s therapy could boost antibiotics against drug-resistant bacteria in CF patients
Privately-held Synspira touted a study today of its inhaled glycopolymer-based therapeutic with antibiotics as a potential treatment for pulmonary infection caused by the Burkholderia cepacia complex in patients with cystic fibrosis. The study was published in PLOS One. Synspira’s lead polycationic glycopolymer, SNSP113, was studied in combination with tobramycin and meropenem. These antibiotics, as well as ceftazidime, are often used to treat Bcc infections in patients with cystic fibrosis. However, Synspira said the microbial agents have demonstrated limited efficacy in the past. Get t...
Source: Mass Device - July 12, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Research & Development Respiratory synspira Source Type: news

Celebrating 10 years of success for Infusion
As the business took off, more space was needed, and the company moved in 2009 to “real” office space just up the road in Haddam, CT, across the street from the Connecticut River, eventually employing a staff of 10 that year. A year later, in 2010, Infusion had doubled in size and became part of the UDG/Ashfield family. Infusion continued to grow at a steady pace into new therapeutic areas with more clients and employees, and in October 2016, Infusion left its country setting and moved into larger corporate offices in downtown Middletown, CT. Our staff now comprises 45 people and includes account executives, me...
Source: Ashfield Healthcare News - July 11, 2017 Category: Pharmaceuticals Authors: Sarah Edwards Tags: Ashfield Source Type: news

New MRI agent shows promise for tumors
Researchers from the University of Massachusetts have developed a protein-based...Read more on AuntMinnie.comRelated Reading: Is ferumoxytol the alternative to gadolinium MRI agents? Glucose-MRI technique at 7T aids tumor evaluation Short breast MRI protocol works for cancer detection Novel MRI scans could aid in cystic fibrosis MRI can replace biopsy for prostate cancer surveillance (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 7, 2017 Category: Radiology Source Type: news

​Vertex raises price of top-selling cystic fibrosis drug for first time
Vertex Pharmaceuticals has raised the price of its best-selling cystic fibrosis drug for the first time, in a move that could boost revenues at the Boston-based company. The decision by Vertex (Nasdaq: VRTX) to increase the list price of Orkambi by 5 percent, to around $273,000 per year before discounts, was first reported by Cowen analyst Phil Nadeau in a note on Wednesday morning and later confirmed by a spokeswoman for the company. Vertex had not previously ra ised the price of Orkambi, which… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 5, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Living while dying: Life when you're born with cystic fibrosis
(Source: CNN.com - Health)
Source: CNN.com - Health - July 5, 2017 Category: Consumer Health News Source Type: news

Celebrating life by confronting death
Claire Wineland has cystic fibrosis, a terminal illness, and she's working to help others understand what it's like to be sick. (Source: CNN.com - Health)
Source: CNN.com - Health - July 5, 2017 Category: Consumer Health News Source Type: news

CF patients and physicians use shared decision-making tool to determine regimens
(University of Cincinnati Academic Health Center) Physician-researchers at the University of Cincinnati have developed a computerized decision-making model to promote shared decision-making with cystic fibrosis patients. The tool takes into account patients' preferences for measures of lung function and health along with the latest medical evidence for effective treatment to help patients prioritize home treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 3, 2017 Category: International Medicine & Public Health Source Type: news

Cystic fibrosis biotech Synspira launches
California-based Synedgen has spun out its experimental cystic fibrosis treatments into a new biotech to be based in the Boston area, with an eye toward complementing existing drugs for the lung disease. The new company, called Synspira, launched on Thursday with $8 million in financing from an anonymous investor and an exclusive license to privately-held Synedgen’s preclinical program for cystic fibrosis. Synspira is operating virtually — the CEO, Synedgen chief operating officer Shenda Baker ,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 30, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Cystic fibrosis biotech Synspira launches
California-based Synedgen has spun out its experimental cystic fibrosis treatments into a new biotech to be based in the Boston area, with an eye toward complementing existing drugs for the lung disease. The new company, called Synspira, launched on Thursday with $8 million in financing from an anonymous investor and an exclusive license to privately-held Synedgen’s preclinical program for cystic fibrosis. Synspira is operating virtually — the CEO, Synedgen chief operating officer Shenda Baker ,… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 30, 2017 Category: American Health Authors: Max Stendahl Source Type: news

Synspira raises $8m for inhaled pulmonary therapies
Privately-held Synspira said today that raised $8 million from an unnamed private investor to bring its inhaled cystic fibrosis therapy into a Phase I safety study. The Boston-based company was founded earlier this year and is focused on developing inhaled therapies for pulmonary diseases, including cystic fibrosis, chronic obstructive pulmonary disease and pneumonia. Synspira holds an exclusive field license to Synedgen’s Glycomics Technology platform and its pulmonary delivery assets. Get the full story at our sister site, Drug Delivery Business News. The post Synspira raises $8m for inhaled pulmonary the...
Source: Mass Device - June 29, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Funding Roundup Respiratory synspira Source Type: news

Mount Sinai, Pfizer renew research collaboration, building on strong foundation
(The Mount Sinai Hospital / Mount Sinai School of Medicine) The Icahn School of Medicine at Mount Sinai and Pfizer Inc.'s Centers for Therapeutic Innovation (CTI) today announced the renewal of an agreement designed to identify and advance new drug candidates linked to major diseases, such as cancer, rheumatoid arthritis, Crohn's disease, colitis, heart failure, Alzheimer's disease, and cystic fibrosis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 27, 2017 Category: Cancer & Oncology Source Type: news

Cystic fibrosis alters the structure of mucus in airways
(University of Iowa Health Care) Cystic fibrosis (CF) alters the structure of mucus produced in airway passages. In pigs affected by CF, mucus strands (made of MUC5B protein) are more tangled than normal, and the sheets of mucus (made of MUC5AC protein) that cover the strands are denser. These structural abnormalities may help explain why people with CF have difficulty clearing mucus from their lungs. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 27, 2017 Category: International Medicine & Public Health Source Type: news

Can coffee machines and kettles spread toxic spores?
Conclusion This laboratory study suggests that under humid conditions, indoor surfaces like wallpaper may be colonised by fungi that produce toxic particles – some of which may be small enough to be inhaled. But it's important that these findings aren't taken too far out of context at this stage. The study was carried out in highly experimental circumstances where both temperature and humidity were optimised for maximal fungal growth. We can't know for sure that these circumstances would be typical of indoor environments, even bathrooms or kitchens, if they're well ventilated. The UK media has applied these findin...
Source: NHS News Feed - June 26, 2017 Category: Consumer Health News Tags: Heart/lungs Lifestyle/exercise Source Type: news

How a woman with cystic fibrosis defied expectations
Janka Penther was born with cystic fibrosis (CF), a crippling genetic condition, and doctors had told her she wouldn't live past 21 years old. When she hit 30, she was planning her own funeral. (Source: the Mail online | Health)
Source: the Mail online | Health - June 25, 2017 Category: Consumer Health News Source Type: news

UCLA Mattel Children ’s Hospital and Miller Children’s & Women ’s Hospital plan strategic affiliation
Two leading children ’s hospitals —UCLA Mattel Children ’s Hospital, part of UCLA Health, and  Miller Children ’s& Women ’s Hospital Long Beach, part of  MemorialCare Health System— announced today their intent to form a strategic affiliation that brings together their academic, clinical and research expertise, and resources to enhance children’s health care services in Southern California.The two organizations, which share similar missions and values, plan to establish a wider geographic pediatric collaboration that strengthens and broadens their ability to offer the...
Source: UCLA Newsroom: Health Sciences - June 22, 2017 Category: Universities & Medical Training Source Type: news

Bacteria from cystic fibrosis patient could help thwart antibiotic-resistant TB
(American Chemical Society) The number of drug-resistant tuberculosis (TB) cases is rising globally. But a newly discovered natural antibiotic -- produced by bacteria from the lung infection in a cystic fibrosis patient -- could help fight these infections. Lab testing reported in the Journal of the American Chemical Society shows that the compound is active against multi-drug resistant strains. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 14, 2017 Category: Biology Source Type: news

Lumacaftor, Ivacaftor Linked to Improved Lung Function in CF
Findings in patients aged 6 to 11 years with cystic fibrosis homozygous for F508del - CFTR (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - June 12, 2017 Category: Respiratory Medicine Tags: Pediatrics, Pharmacy, Pulmonology, Journal, Source Type: news

New Drug Combo Effective for Cystic Fibrosis in Kids New Drug Combo Effective for Cystic Fibrosis in Kids
Young children with cystic fibrosis could see rapid improvements in symptoms by taking a combination of 2 drugs, a study has found.WebMD Health News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 9, 2017 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Cystic fibrosis drug stops 'irreversible' damage in kids
Charities claim the latest findings on Orkambi, published by researchers at the University of Toronto, are exciting, as it can do the unthinkable by reversing lasting damage in young patients. (Source: the Mail online | Health)
Source: the Mail online | Health - June 9, 2017 Category: Consumer Health News Source Type: news

Drug combination improves lung function in cystic fibrosis patients
New approach may act on errors caused by the gene mutation Related items fromOnMedica Newborns screened for four additional genetic conditions Experts predict sharp rise in cystic fibrosis cases by 2025 Drug boosts bone density in cystic fibrosis (Source: OnMedica Latest News)
Source: OnMedica Latest News - June 9, 2017 Category: UK Health Source Type: news

Vertex shares soar in 2017, and the best may be yet to come
Vertex Pharmaceuticals has been the top-performing stock in the S&P 500 so far this year, and further gains could be on the horizon. Shares of Boston-based Vertex (Nasdaq: VRTX), which makes cystic fibrosis drugs, have increased around 70 percent since the beginning of the year. That marks the biggest gain of any company on the S&P 500 during that period. (That fact was pointed out by the Wall Street Journal on Wednesday.) The jump can be attributed in part to the company’s announcement in late… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 8, 2017 Category: American Health Authors: Max Stendahl Source Type: news

Novoteris, LLC Receives FDA and Health Canada Clearance to Start a Phase 2 Clinical Trial of Its Thiolanox(R) Nitric Oxide for the Treatment of Cystic Fibrosis
GARDEN GROVE, Calif., June 5, 2017 -- (Healthcare Sales & Marketing Network) -- Novoteris, LLC, a clinical stage medical device and pharmaceutical developer focused on innovative nitric oxide gas applications, announced today that both the US Food and Dru... Biopharmaceuticals, Drug Delivery, FDA Novoteris, Thiolanox, nitric oxide, Cystic Fibrosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 5, 2017 Category: Pharmaceuticals Source Type: news

NIDCR Science News
Having trouble viewing this email? View it as a Web page. Study Redefines HPV-related Head and Neck Cancers​ Virginia Commonwealth University • May 22, 2017​ Grape Seed Extract Could Extend Life of Resin Fillings​​ University of Illinois, Chicago • May 9, 2017​ Scientists Uncover Interactions Between Bacteria that Infect the Lungs in Cystic Fibrosis University of Alabama, Birmingham • April 27, 2017 Mouse Teeth Providing New Insights into Tissue Regeneration Un...
Source: NIDCR Science News - May 31, 2017 Category: Dentistry Source Type: news

Startup Talee Bio is seeking a cure for cystic fibrosis
The gene therapy company was launched by women-led Militia Hill Ventures. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 25, 2017 Category: American Health Authors: John George Source Type: news

Plan early, talk often: normalizing end-of-life planning in the cystic fibrosis clinic
(Source: St. Michael's Hospital News and Media)
Source: St. Michael's Hospital News and Media - May 24, 2017 Category: Hospital Management Tags: Hospital News Source Type: news

MassDevice.com +5 | The top 5 medtech stories for May 23, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Philips picks up airway clearance device dev RespirTech Royal Philips said today it inked a deal to acquire airway clearance solution developer RespirTech for an undisclosed amount. St. Paul, Minn.-based RespirTech was founded ...
Source: Mass Device - May 23, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Philips picks up airway clearance device dev RespirTech
Royal Philips (NYSE:PHG) said today it inked a deal to acquire airway clearance solution developer RespirTech for an undisclosed amount. St. Paul, Minn.-based RespirTech was founded in 2004 and has approximately 210 employees. The company produces airway clearance devices for patients with chronic respiratory conditions, such as chronic obstructive pulmonary disease and cystic fibrosis. Philips said that the addition of RespirTech’s portfolio will allow Philips to “accelerate its growth in respiratory care,” specifically for COPD patients with bronchiectasis. The acquired portfolio includes a clinica...
Source: Mass Device - May 23, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Mergers & Acquisitions Respiratory royal-philips Source Type: news

Interventions for promoting participation in shared decision-making for children and adolescents with cystic fibrosis.
The objectives are as follows: To determine the effectiveness of interventions that promote SDM for children and adolescents with CF aged four to 18 years. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 22, 2017 Category: Consumer Health News Source Type: news

Quvium ’s cough monitor boosts compliance by involving caregivers
When Steven Schmidt worked at Vertex Pharmaceuticals (NSDQ:VRTX), Eric Olson – the man who led the development of the 1st drug to treat the underlying causes of cystic fibrosis – asked Schmidt to look into ways that families could become more engaged with managing a patient’s condition. Olson pointed towards a publication that showed that involving caregivers added 8 years of life expectancy to children with cystic fibrosis. Schmidt, who now serves as founder and CEO of Quvium, took that idea and began development of a wearable cough monitor that alerts patients’ caregivers when a cough is out of th...
Source: Mass Device - May 22, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Patient Monitoring Pharmaceuticals Respiratory Wall Street Beat quvium Source Type: news

Vertex launches college scholarship program for cystic fibrosis patients, families
Vertex Pharmaceuticals has launched a new college scholarship program for people affected by cystic fibrosis, the debilitating and often fatal lung disease that the Boston-based company has spent decades trying to tackle. Vertex (Nasdaq: VRTX) said Friday it had awarded $5,000 each to 40 students nationwide — 26 cystic fibrosis patients and 14 immediate family members — for a total of $200,000. The scholarships will help to pay for two-year, four-year and graduate degrees. Recipients were chosen… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - May 19, 2017 Category: Health Management Authors: Max Stendahl Source Type: news

Kalydeco Approval Widened for More Types of Cystic Fibrosis
Title: Kalydeco Approval Widened for More Types of Cystic FibrosisCategory: Health NewsCreated: 5/18/2017 12:00:00 AMLast Editorial Review: 5/19/2017 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - May 19, 2017 Category: Respiratory Medicine Source Type: news

FDA OKs Kalydeco for Additional Mutations in Cystic Fibrosis
Decision based on results of laboratory testing and previous clinical trials (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - May 19, 2017 Category: Respiratory Medicine Tags: Gastroenterology, Pediatrics, Pharmacy, Pulmonology, Institutional, Source Type: news

Kalydeco Approval Widened for More Types of Cystic Fibrosis
Laboratory evidence used to expand approval (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - May 18, 2017 Category: Respiratory Medicine Tags: Pharmacy, Pulmonology, FDA Approvals, Source Type: news

Cystic fibrosis study offers new understanding of silent changes in genes
Researchers studying the root cause of cystic fibrosis have made a major advance in our understanding of silent gene changes with implications for the complexity of cystic fibrosis. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 18, 2017 Category: Science Source Type: news

Kalydeco Approval Widened for More Types of Cystic Fibrosis
THURSDAY, May 18, 2017 -- The U.S. Food and Drug Administration says it has expanded approval for the cystic fibrosis drug Kalydeco (ivacaftor) to include 33 mutations of the disease, up from the previous 10 mutations. In a media release, the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 18, 2017 Category: General Medicine Source Type: news

Vertex boosts Kalydeco sales forecast after FDA approves for more patients
Boston-based Vertex Pharmaceuticals on Wednesday raised its 2017 revenue forecast for cystic fibrosis drug Kalydeco after the FDA approved the treatment for patients with additional kinds of genetic mutations. Vertex (Nasdaq: VRTX) announced that the agency had approved Kalydeco for patients ages 2 and older who have any of 23 mutations that collectively affect more than 900 people in the U.S. The drug was already approved for 10 mutations. As a result of the approval, the company said it was increasin g… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 18, 2017 Category: American Health Authors: Max Stendahl Source Type: news

Cystic fibrosis study offers new understanding of silent changes in genes
(University of Bristol) Researchers studying the root cause of cystic fibrosis have made a major advance in our understanding of silent gene changes with implications for the complexity of cystic fibrosis. The findings are published today in [May 16] PLoS Biology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 18, 2017 Category: International Medicine & Public Health Source Type: news

FDA Widens Use of Ivacaftor Again for Cystic Fibrosis FDA Widens Use of Ivacaftor Again for Cystic Fibrosis
In what is hailed as a victory for precision medicine, the agency expanded the drug's indication to cover more gene mutations that cause the life-shortening disorder.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 17, 2017 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news

FDA Broadens Kalydeco Indication in Cystic Fibrosis
(MedPage Today) -- Approval for additional mutations based on lab results (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 17, 2017 Category: American Health Source Type: news

FDA expands approved use of Kalydeco to treat additional mutations of cystic fibrosis
The U.S. Food and Drug Administration today expanded the approved use of Kalydeco (ivacaftor) for treating cystic fibrosis. The approval triples the number of rare gene mutations that the drug can now treat, expanding the indication from the treatment of 10 mutations, to 33. The agency based its decision, in part, on the results of laboratory testing, which it used in conjunction with evidence from earlier human clinical trials. The approach provides a pathway for adding additional, rare mutations of the disease, based on laboratory data. (Source: Food and Drug Administration)
Source: Food and Drug Administration - May 17, 2017 Category: American Health Source Type: news

FDA Expands Approved Use of Kalydeco to Treat Additional Mutations of Cystic Fibrosis
May 17, 2017 -- The U.S. Food and Drug Administration today expanded the approved use of Kalydeco (ivacaftor) for treating cystic fibrosis. The approval triples the number of rare gene mutations that the drug can now treat, expanding the indication... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 17, 2017 Category: Drugs & Pharmacology Source Type: news

Cystic fibrosis study offers new understanding of silent changes in genes
Researchers studying the root cause of cystic fibrosis have made a major advance in our understanding of silent gene changes with implications for the complexity of cystic fibrosis. The findings are published today in [16 May] PLoS Biology. (Source: University of Bristol news)
Source: University of Bristol news - May 17, 2017 Category: Universities & Medical Training Tags: Health, International, Research; Faculty of Biomedical Sciences, Faculty of Biomedical Sciences, School of Physiology and Pharmacology, Institutes, Elizabeth Blackwell; Press Release Source Type: news

' Molecular prosthetics' can replace missing proteins to treat disease
Researchers have demonstrated that a small molecule can transport iron in human cells and live animals when proteins that normally do the same job are missing, a condition that often causes severe anemia in patients. Such'molecular prosthetics'might treat a host of incurable diseases caused by protein deficiencies, such as anemias, cystic fibrosis or certain types of heart disease. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 11, 2017 Category: Science Source Type: news

To The Members Of Congress Who Voted To Deny Health Care For My Grandkids
All of the members of the House of Representatives who voted to repeal the Affordable Care Act (ACA), also known as Obamacare, and pass the replacement bill are cowards. They rushed this bill through the House in response to bullying from President Trump, the Freedom Caucus, and Speaker Ryan, many without even reading it. They did this not because most of them believed in their hearts it was a good bill but because they put politics before people. Because some of those people who will be hurt by this bill are my grandkids, I am “mad as hell and I won’t take it anymore.” I have a grandchild born with cysti...
Source: Healthy Living - The Huffington Post - May 8, 2017 Category: Consumer Health News Source Type: news